GLYCOMIMETICS INC
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
CBIO$13.65+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, · | ||||||||||
| · · 2023 · · 2022 · · 2021 | ||||||||||
| | | | | | | | | | | |
| Revenue from collaboration and license agreements | | $10,000 | | $75,000 | | $1,159,767 | | |||
| | | | | | | | | | | |
| Costs and expenses: | | | | | | | | | | |
| Research and development expense | | 20,071,656 | | 28,390,879 | | 47,491,567 | | |||
| General and administrative expense | | 19,213,637 | | 19,087,443 | | 17,115,405 | | |||
| Total costs and expenses | | 39,285,293 | | 47,478,322 | | 64,606,972 | | |||
| Loss from operations | | (39,275,293) | | (47,403,322) | | (63,447,205) | | |||
| Interest income | | 2,375,873 | | 714,520 | | 19,768 | | |||
| Net loss and comprehensive loss | | $(36,899,420) | | $(46,688,802) | | $(63,427,437) | | |||
| Basic and diluted net loss per common share | | $(0.58) | | $(0.89) | | $(1.23) | | |||
| Basic and diluted weighted-average number of common shares outstanding | | 63,342,465 | | 52,531,173 | | 51,453,204 | | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.